HOME >> BIOLOGY >> NEWS
Prenatal exposure to glucocorticoids has long-term deleterious effects on newborns

Researchers at the University of Edinburgh in the United Kingdom have found that, as for rodents and other nonprimates, prenatal exposure of nonhuman primate African vervet monkeys (Chloroceus aethiops) to glucocorticoids has long-lasting deleterious effects on cardiovascular, metabolic, and neuroendocrine function.

Glucocorticoids are still widely used in obstetric practice. So, Jonathan Seckl and colleagues set out to determine the relevance to human pregnancy of rodent and nonprimate data indicating that prenatal exposure to glucocorticoids (through either the administration of dexamethasone or severe maternal stress) has long-lasting deleterious effects. In the study, which appears online on March 22 in advance of publication in the April print issue of the Journal of Clinical Investigation, they show that although the birth weight of offspring born to nonhuman primate African vervet monkeys treated with dexamethasone from mid-gestation onward did not differ from that of offspring born to untreated animals, the high levels of prenatal dexamethasone impaired postnatal growth, impaired glucose-insulin homeostasis, increased blood pressure 12 months after birth, and increased the production of cortisol in response to mild stress. These data suggest that both repeated glucocorticoid therapy and severe maternal stress late in gestation are likely to have long-term deleterious effects on developing human fetuses.


'"/>

Contact: Karen Honey
press_releases@the-jci.org
215-573-1850
Journal of Clinical Investigation
22-Mar-2007


Page: 1

Related biology news :

1. Prenatal stress keeps infants, toddlers up at night, study says
2. Prenatal alcohol exposure alters brain activity in the frontal-striatal areas
3. Prenatal toxicity linked to immune dysfunctions in later life
4. Prenatal nicotine exposure can lead to cardiac function reprogramming in adult offspring
5. Prenatal cocaines lasting cellular effects
6. Prenatal alcohol exposure appears to increase an infants stress response
7. Prenatal vitamins may reduce risk of brain tumors in children
8. Prenatal health strongly influences future economic success
9. Prenatal nicotine exposure reduces breathing response of newborns...
10. Prenatal genistein in soy reduces obesity in offspring
11. Prenatal pesticide exposure and high blood pressure and a decreased ability to copy shapes

Post Your Comments:
(Date:11/21/2014)... VIEW, Calif. , Nov. 20, 2014 ... higher driver efficiency are piloting the North American and ... number of accidents growing, gesture recognition systems that are ... make a mark in the industry. ... the Automotive Gesture Recognition Market in Europe ...
(Date:11/21/2014)... 20, 2014   Atmel® Corporation (NASDAQ: ... and touch technology solutions, today launched the industry,s first ... the widest V cc range from 1.7V to ... faster I 2 C bus communication speeds, and are ... making them ideal for consumer, industrial, computer, and medical ...
(Date:11/18/2014)... , Nov. 17, 2014   ... EMC collaborate to develop The Partners Data Lake, ... The Partners Data Lake will allow researcher and ... diagnostics, treatment and the lives of patients ... and clinical activities across the Partners system, breaking ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5
(Date:12/19/2014)... , Dec. 18, 2014 Egenix, Inc. is ... been elected Chairman of the Board, to succeed Donald ... CEO, but will continue as a member of the Board.  ... has added to the company over almost twenty years, the ... The Board of Directors has established a Search Committee to ...
(Date:12/17/2014)... USA (PRWEB) December 16, 2014 ... manager at Philipps- Universität Marburg’s Department of Physics, ... photonics, in the newly released SPIE Women ... never be too shy to ask questions.” , ... technology, engineering, and mathematics) occupations ranging from university ...
(Date:12/17/2014)... Indianapolis, IN (PRWEB) December 17, 2014 ... for Laboratory Excellence following its most recent COLA ... Accreditation by COLA, a national healthcare accreditation organization. ... rigid standards of quality in day-to-day operations, demonstrate ... and pass a rigorous on-site laboratory survey. ...
(Date:12/17/2014)... 17, 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... acquisition, development and commercialization of innovative therapeutics addressing cancer ... with a primary commercial focus on China ... a Type C meeting with the U.S. Food and ... held in February 2015.  During this meeting the Company ...
Breaking Biology Technology:Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 3Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5
Cached News: